Second Sight to Discuss First Quarter 2017 Financial Results on May 3, 2017 Conference Call
April 25 2017 - 8:00AM
Business Wire
Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer,
manufacturer and marketer of implantable visual prosthetics that
are intended to provide some useful vision to blind patients, will
release its first quarter financial results on Wednesday, May 3,
2017, after the close of the U.S. financial markets.
Dr. Robert Greenberg, Chairman, Will McGuire, President and
Chief Executive Officer, and Tom Miller, Chief Financial Officer,
will host a conference call to discuss the results as follows:
Date Wednesday, May 3, 2017 Time 4:30
p.m. EDT Toll free (U.S.) (800) 406-9725 International (312)
281-1202 Webcast (live and replay)
www.secondsight.com under the ‘Investor
Relations’ section.
A replay of the conference call will be available for two weeks
after the call's completion by dialing (800) 633-8284 (U.S.)
or (402) 977-9140 (International). The conference ID for the
replay is 21850167. The archived webcast will be available for 30
days via the aforementioned URL.
About the Argus® II Retinal Prosthesis
System
Second Sight's Argus II System provides electrical stimulation
that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe
to profound Retinitis Pigmentosa. The Argus II works by converting
images captured by a miniature video camera mounted on the
patient's glasses into a series of small electrical pulses, which
are transmitted wirelessly to an array of electrodes implanted on
the surface of the retina. These pulses stimulate the retina's
remaining cells, intending to result in the perception of patterns
of light in the brain. The patient must learn to interpret these
visual patterns, having the potential to regain some visual
function. The Argus II was the first artificial retina to receive
widespread approval, and is offered at approved centers in Canada,
France, Germany, Italy, Netherlands, Saudi Arabia, Spain,
Switzerland, Turkey, United Kingdom, and the U.S.
About Second Sight
Second Sight's mission is to develop, manufacture and market
innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has
developed and manufactures the Argus® II Retinal Prosthesis System.
Second Sight is currently conducting a trial to test the safety and
utility of the Argus II in individuals with Dry Age-Related Macular
Degeneration. Second Sight is also developing the Orion™ I
Visual Cortical Prosthesis that is intended to restore some vision
to individuals who are blind due to many causes other than
preventable or treatable conditions. U.S. Headquarters are in
Sylmar, CA, and European Headquarters are in Lausanne, Switzerland.
For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange
Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this
release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as
"estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should"
and similar expressions or the negative versions thereof and which
also may be identified by their context. All statements that
address operating performance or events or developments that Second
Sight expects or anticipates will occur in the future are
forward-looking statements. While management has based any forward
looking statements included in this release on its current
expectations, the information on which such expectations were based
may change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described
in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our
Annual Report on Form 10-K as filed on March 16,
2017, and our other reports filed from time to time with
the Securities and Exchange Commission. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425005506/en/
Investor Relations:Institutional InvestorsIn-Site
Communications, Inc.Lisa Wilson,
212-452-2793Presidentlwilson@insitecony.comorIndividual InvestorsMZ
North AmericaGreg Falesnik, 949-385-6449Managing
Directorgreg.falesnik@mzgroup.us
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024